Summit Investment Advisors Inc. Sells 503 Shares of Eli Lilly and Company (NYSE:LLY)

Summit Investment Advisors Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,384 shares of the company's stock after selling 503 shares during the quarter. Eli Lilly and Company makes up about 14.0% of Summit Investment Advisors Inc.'s investment portfolio, making the stock its 25th largest holding. Summit Investment Advisors Inc.'s holdings in Eli Lilly and Company were worth $15,736,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Stamos Capital Partners L.P. grew its position in shares of Eli Lilly and Company by 70.2% during the 4th quarter. Stamos Capital Partners L.P. now owns 1,940 shares of the company's stock valued at $1,498,000 after acquiring an additional 800 shares during the period. Bragg Financial Advisors Inc grew its holdings in Eli Lilly and Company by 3.4% during the fourth quarter. Bragg Financial Advisors Inc now owns 12,013 shares of the company's stock valued at $9,274,000 after purchasing an additional 397 shares during the period. BTG Pactual Asset Management US LLC increased its position in Eli Lilly and Company by 18.8% in the fourth quarter. BTG Pactual Asset Management US LLC now owns 2,127 shares of the company's stock worth $1,692,000 after buying an additional 336 shares in the last quarter. Granite Investment Partners LLC raised its stake in shares of Eli Lilly and Company by 11.6% in the fourth quarter. Granite Investment Partners LLC now owns 41,806 shares of the company's stock worth $32,274,000 after buying an additional 4,335 shares during the period. Finally, WealthTrust Axiom LLC lifted its position in shares of Eli Lilly and Company by 1.4% during the 4th quarter. WealthTrust Axiom LLC now owns 10,544 shares of the company's stock valued at $8,140,000 after buying an additional 143 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Remove Ads

Eli Lilly and Company Trading Up 0.3 %

LLY traded up $2.20 on Tuesday, hitting $756.55. The company had a trading volume of 2,439,271 shares, compared to its average volume of 3,387,076. The business's fifty day simple moving average is $832.96 and its 200 day simple moving average is $821.54. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a market cap of $717.34 billion, a PE ratio of 64.61, a PEG ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.13% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on LLY shares. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Citigroup cut their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Guggenheim dropped their price objective on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research note on Monday. Finally, The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Two research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,012.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.